Limontar
Registration number: Р N000176/01
Trade name: Limontar®
International non-proprietary name: Citric acid + Succinic acid.
Dosage form: soluble tablets.
Ingredients per 1 tablet: active ingredients: succinic acid – 200 mg, citric acid monohydrate – 50 mg; excipients: magnesium stearate – 3 mg.
Appearance: round biconvex tablets of white or almost white colour.
Therapeutic category: metabolic drug.
ATC code: A15.
Pharmacological properties
Pharmacodynamics:
Limontar® is a regulator of tissue metabolism; it enhances redox processes, the formation of adenosine triphosphate (ATP), which determines its antihypoxic and antioxidant properties; therefore, the drug is capable to:
- activate the functions of organs and tissues;
- increase the reactivity of the body;
- improve the course of pregnancy, including growth and development of the fetus;
- improve mental and physical efficiency;
- enhance the secretion of gastric juice, the formation of hydrochloric acid, increase appetite;
- reduce the toxic effect of alcohol.
The effect of Limontar® appears in 10–20 minutes after administration.
Pharmacokinetics: succinic and citric acids completely decompose to water and carbon dioxide, accumulation in the body does not occur.
Indications for use
Indications for use:
As a means to increase the nonspecific reactivity of the body in pregnant women, to improve its adaptive and compensatory protective capabilities in order to prevent complications in case of hypoxia, fetal malnutrition, or miscarriage.
As a test breakfast for evaluation of gastric secretory and acid-forming functions (diagnostic value of the Limontar® and histamine is equivalent).
For the prevention of alcohol intoxication; in the treatment of acute alcoholic intoxication of mild and moderate severity to reduce the toxic effects of alcohol and post-intoxication disorders; in complex therapy for the treatment of heavy drinking in patients with chronic alcoholism.
During the alcohol withdrawal syndrome; for the complex treatment of asthenic vegetative disorders (general weakness, decreased efficiency and appetite).
Contraindications: hypersensitivity to the components of the drug, arterial hypertension, ischemic heart disease (including angina pectoris), glaucoma, gastric ulcer and duodenal ulcer in the acute stage, late gestosis (severe form).
Dosage and administration
Administration of the drug during pregnancy and breastfeeding:
The use of the drug during pregnancy is possible in the first trimester (at 12-14 weeks of gestation), in the second trimester (at 24-26 weeks of gestation) and in the third trimester (10-25 days before delivery), on the recommendation of an OB (more in the sections "Indications for use", " Dosage and administration").
The use of the drug during breastfeeding is not recommended (due to the lack of research results on the effectiveness and safety of the drug during this period).
Dosage and administration: take orally before meals. Before taking, the tablet should be crushed and dissolved in drinking water with a pinch of baking soda or in mineral water.
For pregnant women: in the first trimester (at 12-14 weeks of gestation), in the second trimester (at 24-26 weeks of gestation) and in the third trimester (10-25 days before delivery), 1 tablet per day within 10 days. The total dose of the drug Limontar® during pregnancy is 5-7.5 g.
As a "test breakfast" for the study of the secretory and acid-forming function of the stomach: 1 tablet fasted, dissolved previously in 10-15 ml of water.
For the prevention of alcohol intoxication: 1 tablet in 20-60 minutes before alcohol intake.
In a state of acute alcoholic intoxication: 1 tablet 2-4 times a day with an interval of 1-2.5 hours.
In case of heavy drinking: 1 tablet 3-4 times a day for 4-10 days; can be used independently or together with standard therapy.
In case of feeling of heaviness in the upper abdomen Limontar® can be used after a meal.
Side effects: of pain in the upper abdomen is possible (usually it disappears in 3-5 minutes); allergic reactions; increased secretion of gastric juice; increased blood pressure.
Overdose: no cases of overdose have been identified for now.
Drug interactions: weakens the effect of hypnotics and tranquilizers.
Special warnings: the tablet must be dissolved before use.
Possible effects on ability to drive vehicles or use potentially dangerous machines:
The use of the drug does not affect the ability to perform potentially hazardous activities that require an increased concentration and reaction rate (drivers, operators (including of moving mechanisms), controllers).
Package: sublingual tablets, 50 mg +200 mg. 30 tablets in a blister made of polyvinyl chloride film and aluminum foil. 1 blister together with instructions for use in a cardboard box.
Storage conditions: in original package (blister in a pack) at a temperature not exceeding 25 С°.
Keep out of the reach of children.
Shelf life: 3 years.
Do not use after labeled expiration date.
Prescription status: no prescription required.
Name and address of manufacturer/company which accepts customer complaints: LLC “Medical Scientific and Production Complex “BIOTIKI”. Russia, 115404, Moscow, 6th Radialnaya st., 24, bldg. 1, 2, 14, 15.
Phone: +7 (495) 327-86-30
Toll-free hotline in Russia: 8-800-100-32-22
